Ask about this productRelated genes to: SERPINB4 Blocking Peptide
- Gene:
- SERPINB4 NIH gene
- Name:
- serpin family B member 4
- Previous symbol:
- SCCA2
- Synonyms:
- PI11, LEUPIN, SCCA-2, SCCA1
- Chromosome:
- 18q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1995-09-15
- Date modifiied:
- 2016-04-06
Related products to: SERPINB4 Blocking Peptide
Related articles to: SERPINB4 Blocking Peptide
- Pancreatic cancer is one of the most lethal malignancies, with limited therapeutic options. In this exploratory trial, we aimed to evaluate the efficacy and safety of nanoparticle polymeric micellar paclitaxel (pm-Pac) combined with gemcitabine as first-line treatment for metastatic pancreatic cancer (mPC). - Source: PubMed
Publication date: 2026/05/01
Lyu NanWang QianqianJiang KuirongXu DongWu YangZhang KaiWei JishuChen JianminGuo FengLu ZipengXiao BinChen GuoshengWu JunliGao WentaoWang YuqiWang FufengTu Min - Cervical cancer remains a significant health burden worldwide, particularly in patients with markedly elevated pretreatment serum squamous cell carcinoma antigen levels (≥ 10 ng/mL), who often have poor outcomes. Accurate prognostic tools for this high-risk population are limited. - Source: PubMed
Publication date: 2026/03/07
Zhao YiweiZhao ChutongLiu YujieWang YuanZhang YunyanLiu Sijia - Early detection of oesophageal squamous cell carcinoma (ESCC) is critical for improving survival, yet current screening is hampered by the lack of effective, non-invasive methods. Here, we developed and prospectively validated an extracellular vesicle (EV) protein-based blood test for the preclinical detection of ESCC. We first engineered BarFlare, a high-sensitivity platform for serum EV protein analysis, and identified a novel biomarker panel that includes EV-associated squamous cell carcinoma antigen (SCC) and matrix metalloproteinase-13 (MMP13). These biomarkers were integrated with clinical factors into an interpretable multi-criteria decision-making classification fusion (MCF) machine-learning framework. The MCF model was trained and validated in prospective, multicentre diagnostic cohorts (n = 1018), and its preclinical detection capability was assessed in a prospective, population-based longitudinal cohort. The MCF framework accurately distinguished patients with ESCC from healthy controls in a test set (AUC, 0.987) and two external validation cohorts (AUCs, 0.926 and 0.960), including those with early-stage disease (AUCs, 0.901-0.980). Critically, in the longitudinal cohort, the framework identified individuals who would later develop ESCC from their baseline blood samples with a median lead time of 34.9 months (range, 0.4-72.5) before clinical diagnosis (AUC, 0.864; sensitivity, 73.3%; specificity, 82.2%). The risk score of the model correlated with time to diagnosis, and its dynamic increase significantly outperformed that of traditional serum SCC for preclinical risk stratification. Our validated, blood-based EV protein signature not only accurately detects prevalent ESCC but also identifies high-risk individuals years before clinical presentation, providing a powerful, non-invasive tool that supports risk-stratified screening and creates a critical window for early, potentially curative intervention. Trial Registration: Chinese Clinical Trial Registry identifiers: ChiCTR2200066733 and ChiCTR2200065610. - Source: PubMed
Wang YuXing ShanWu Ya-XianXue NingChen Pei-MinJin Run-XianXu Yi-WeiJi Ming-FangPeng Yu-HuiLiu Yuan-TaoChen Li-NaWu MengJiang Zi-YingXie Shang-HangLuo Yi-LingZhang BiaoOu Xin-YuanHuang QiTian Bo-YuLing LiCao Su-MeiLiu Wan-LiZeng Mu-ShengZhong Qian - This study aimed to evaluate the expression of selected immunohistochemical (IHC) markers and serum squamous cell carcinoma antigen (SCC-Ag) in vulvar squamous cell carcinoma (VSCC), and to investigate associations with recurrence and death using molecular clustering and diagnostic performance analyses. - Source: PubMed
Publication date: 2026/02/12
Della Corte LuigiPalumbo MarioMignogna ChiaraVarricchio SilviaCarbone GianluigiSirica RosaInsabato LuigiTerracciano DanielaBifulco Giuseppe - The objective of this study was to identify key idiopathic pulmonary fibrosis (IPF) related genes, thereby establishing a novel IPF diagnostic/warning panel and proposing drugs against IPF based on the strategy of targeting key genes. - Source: PubMed
Publication date: 2026/01/15
Song YuMeng XianglinTian JiaqiHao YunheZeng KaiZhang LikunZhang JiannanZhang KailiXin YuWang ChangsongYu Kaijiang